Simon H S Pearce

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1621585/publications.pdf Version: 2024-02-01

		44042	29127
137	11,257	48	104
papers	citations	h-index	g-index
141	141	141	11758
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Adjuvant Rituximab—Exploratory Trial in Young People With Graves Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 743-754.	1.8	15
2	Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide. European Thyroid Journal, 2022, 11, .	1.2	3
3	Outcomes of Thyroid Dysfunction in People Aged Eighty Years and Older: An Individual Patient Data Meta-Analysis of Four Prospective Studies (Towards Understanding Longitudinal International Older) Tj ETQq1	10.28431	4 rg B T /Overl
4	MANAGEMENT OF ENDOCRINE DISEASE: Residual adrenal function in Addison's disease. European Journal of Endocrinology, 2021, 184, R61-R67.	1.9	6
5	Residual Adrenal Function in Autoimmune Addison's Disease—Effect of Dual Therapy With Rituximab and Depot Tetracosactide. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1250-e1259.	1.8	14
6	Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2020, 324, 249.	3.8	33
7	New Therapeutic Horizons for Graves' Hyperthyroidism. Endocrine Reviews, 2020, 41, 873-884.	8.9	56
8	Differentiated thyroid cancer mortality by disease stage in northern England. Clinical Endocrinology, 2020, 93, 61-66.	1.2	2
9	Natural History of Adrenal Steroidogenesis in Autoimmune Addison's Disease Following Diagnosis and Treatment. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2322-2330.	1.8	7
10	Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis. European Journal of Endocrinology, 2020, 183, 637-645.	1.9	14
11	Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial. BMJ Open, 2019, 9, e024705.	0.8	7
12	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid, 2019, 29, 1003-1011.	2.4	72
13	Thyroid Hormone Therapy for Subclinical Hypothyroidism. JAMA - Journal of the American Medical Association, 2019, 321, 804.	3.8	5
14	Older patients' experience of primary hypothyroidism: A qualitative study. Health Expectations, 2018, 21, 628-635.	1.1	2
15	Isolation of a multipotent mesenchymal stem cell-like population from human adrenal cortex. Endocrine Connections, 2018, 7, 617-629.	0.8	4
16	Low-dose levothyroxine did not improve symptoms in asymptomatic older people with subclinical hypothyroidism. BMJ Evidence-Based Medicine, 2018, 23, 39-40.	1.7	0
17	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	5.5	128
18	Graves' Disease. Endocrinology, 2018, , 429-449.	0.1	0

#	Article	IF	CITATIONS
19	An unusual cause of adrenal insufficiency and bilateral adrenal masses. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	1
20	Tremelimumab-Induced Graves Hyperthyroidism. European Thyroid Journal, 2017, 6, 167-170.	1.2	42
21	Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with primary hypothyroidism—protocol for a systematic review. Systematic Reviews, 2017, 6, 60.	2.5	16
22	Improving the prehospital safety of steroidâ€dependent patients in northern England: A hospitalâ€initiated ambulance service registration pathway. Clinical Endocrinology, 2017, 87, 881-882.	1.2	2
23	Thyroid hormones and cardiovascular disease. Nature Reviews Cardiology, 2017, 14, 39-55.	6.1	448
24	Ventriculitis from a pituitary prolactinoma: bacterial or chemical?. British Journal of Neurosurgery, 2017, 31, 262-263.	0.4	2
25	Patients' attitudes and perceptions towards treatment of hypothyroidism in general practice: an in-depth qualitative interview study. BJGP Open, 2017, 1, bjgpopen17X100977.	0.9	11
26	Loperamide-induced hypopituitarism: TableÂ1. BMJ Case Reports, 2016, 2016, bcr2016216384.	0.2	4
27	A Variant in the <i>BACH2</i> Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3865-3869.	1.8	18
28	Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4385-4394.	1.8	70
29	Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) – results from the feasibility randomised controlled trial. Thyroid Research, 2016, 9, 5.	0.7	17
30	Subclinical hyperthyroidism: first do no harm. Clinical Endocrinology, 2016, 85, 15-16.	1.2	4
31	Phaeochromocytoma and <scp>ACTH</scp> â€dependent cushing's syndrome: tumour crf secretion can mimic pituitary cushing's disease. Clinical Endocrinology, 2016, 84, 177-184.	1.2	15
32	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry,the, 2016, 3, 117-127.	3.7	30
33	Spontaneous and tetracosactideâ€induced antiâ€ACTH antibodies in man. Clinical Endocrinology, 2016, 84, 489-495.	1.2	4
34	Graves' Disease. Endocrinology, 2016, , 1-21.	0.1	0
35	Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial. Trials, 2015, 16, 115.	0.7	34
36	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	2.1	92

#	Article	IF	CITATIONS
37	Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus. PLoS ONE, 2015, 10, e0123550.	1.1	10
38	Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study). Efficacy and Mechanism Evaluation, 2015, 2, 1-98.	0.9	5
39	Difficult-to-Treat Hyperthyroidism. , 2015, , 1-7.		Ο
40	Association of Autoimmune Addison's Disease with Alleles of STAT4 and GATA3 in European Cohorts. PLoS ONE, 2014, 9, e88991.	1.1	27
41	Saving lives of inâ€patients with adrenal insufficiency: implementation of an alert scheme within the Newcastleâ€uponâ€Tyne Hospitals eâ€Prescribing platform. Clinical Endocrinology, 2014, 81, 937-938.	1.2	7
42	Reply on the Letter by Stott et al. 'The Dilemma of Treating Subclinical Hypothyroidism: Risk that Current Guidelines Do More Harm than Good'. European Thyroid Journal, 2014, 3, 139-140.	1.2	5
43	Current and emerging therapies for Addison's disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 147-153.	1.2	13
44	Residual Adrenal Function in Autoimmune Addison's Disease: Improvement After Tetracosactide (ACTH _{1–24}) Treatment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 111-118.	1.8	31
45	Insufficient evidence to favour prednisolone over hydrocortisone in glucocorticoid replacement. BMJ, The, 2014, 349, g5510-g5510.	3.0	3
46	Diagnosis and management of thyrotoxicosis. BMJ, The, 2014, 349, g5128-g5128.	3.0	55
47	Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED): protocol for a mixed methods feasibility study to assess the clinical utility of lower dose thyroxine in elderly hypothyroid patients: study protocol for a randomized controlled trial. Trials, 2013, 14, 83.	0.7	12
48	The effect of B cell depletion therapy on antiâ€ <scp>TSH</scp> receptor antibodies and clinical outcome in glucocorticoidâ€refractory Graves' orbitopathy. Clinical Endocrinology, 2013, 79, 437-442.	1.2	64
49	Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). BMC Psychiatry, 2013, 13, 205.	1.1	7
50	Prevention and Treatment of Vitamin D Deficiency. Calcified Tissue International, 2013, 92, 207-215.	1.5	15
51	A Review of the Clinical Consequences of Variation in Thyroid Function Within the Reference Range. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3562-3571.	1.8	223
52	2013 ETA Guideline: Management of Subclinical Hypothyroidism. European Thyroid Journal, 2013, 2, 215-228.	1.2	623
53	How should I approach standard endocrine evaluation in patients with coeliac disease?. Clinical Endocrinology, 2013, 79, 464-467.	1.2	0
54	A <scp>UK</scp> epidemic of testosterone prescribing, 2001–2010. Clinical Endocrinology, 2013, 79, 564-570.	1.2	70

#	Article	IF	CITATIONS
55	Anti-neutrophil cytoplasmic antibody (ANCA) associated small-vessel vasculitis in a patient with diabetic nephropathy and autoimmune polyendocrinopathy syndrome (APS) Type 2: a case report. Clinical Nephrology, 2013, 80, 223-226.	0.4	3
56	Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Design, Development and Therapy, 2012, 6, 1.	2.0	75
57	The Thyroid in Mind: Cognitive Function and Low Thyrotropin in Older People. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3438-3449.	1.8	79
58	The role of functionally defective rare germline variants of sialic acid acetylesterase in autoimmune Addison's disease. European Journal of Endocrinology, 2012, 167, 825-828.	1.9	7
59	Levothyroxine Treatment of Subclinical Hypothyroidism, Fatal and Nonfatal Cardiovascular Events, and Mortality. Archives of Internal Medicine, 2012, 172, 811-7.	4.3	195
60	Subclinical Thyroid Disease: Time to Enter the Age of Evidence-Based Medicine. Thyroid, 2012, 22, 765-768.	2.4	4
61	Subclinical Hypothyroidism and Cardiovascular Disease—Reply. Archives of Internal Medicine, 2012, 172, 1523.	4.3	3
62	An ancient founder mutation in PROKR2 impairs human reproduction. Human Molecular Genetics, 2012, 21, 4314-4324.	1.4	31
63	Management of Subclinical Hypothyroidism: The ThyroidologistsÂ' View. European Thyroid Journal, 2012, 1, 45-50.	1.2	8
64	Vitamin D testing. Lancet, The, 2012, 379, 1699-1700.	6.3	2
65	Autoimmune Addison's disease. Presse Medicale, 2012, 41, e626-e635.	0.8	30
66	Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1927-E1932.	1.8	33
67	Many men are receiving unnecessary testosterone prescriptions. BMJ, The, 2012, 345, e5469-e5469.	3.0	19
68	Autoimmune Addison disease: pathophysiology and genetic complexity. Nature Reviews Endocrinology, 2012, 8, 306-316.	4.3	90
69	Perrault syndrome: further evidence for genetic heterogeneity. Journal of Neurology, 2012, 259, 974-976.	1.8	27
70	The role of a nonsynonymous CD226 (DNAX-accessory molecule-1) variant (Gly 307Ser) in isolated Addison's disease and autoimmune polyendocrinopathy type 2 pathogenesis. Clinical Endocrinology, 2011, 75, 165-168.	1.2	7
71	Assessment of a large panel of candidate biomarkers of ageing in the Newcastle 85+ study. Mechanisms of Ageing and Development, 2011, 132, 496-502.	2.2	104
72	Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Human Mutation, 2010, 31, E1089-E1101.	1.1	78

#	Article	IF	CITATIONS
73	How should we treat patients with low serum thyrotropin concentrations?. Clinical Endocrinology, 2010, 72, 292-296.	1.2	50
74	Follow-up of potential novel Graves' disease susceptibility loci, identified in the UK WTCCC genome-wide nonsynonymous SNP study. European Journal of Human Genetics, 2010, 18, 1021-1026.	1.4	16
75	Subclinical thyroid disorders: significance and clinical impact. Journal of Clinical Pathology, 2010, 63, 379-386.	1.0	37
76	The Incidence of Ischemic Heart Disease and Mortality in People with Subclinical Hypothyroidism: Reanalysis of the Whickham Survey Cohort. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1734-1740.	1.8	217
77	Primary hyperparathyroidism: just how â€~primary' is it really?. Therapeutic Advances in Endocrinology and Metabolism, 2010, 1, 191-196.	1.4	1
78	Diagnosis and management of vitamin D deficiency. BMJ: British Medical Journal, 2010, 340, b5664-b5664.	2.4	398
79	Prevalence and Relative Risk of Other Autoimmune Diseases in Subjects with Autoimmune Thyroid Disease. American Journal of Medicine, 2010, 123, 183.e1-183.e9.	0.6	331
80	Discordance for X-Linked Hypophosphataemic Rickets in Identical Twin Girls. Hormone Research in Paediatrics, 2009, 71, 237-244.	0.8	8
81	Programmed Death Ligand 1 (<i>PD</i> - <i>L1</i>) Gene Variants Contribute to Autoimmune Addison's Disease and Graves' Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5139-5145.	1.8	72
82	Trends in thyroid hormone prescribing and consumption in the UK. BMC Public Health, 2009, 9, 132.	1.2	56
83	Thyroid peroxidase forms thionamide-sensitive homodimers: relevance for immunomodulation of thyroid autoimmunity. Journal of Molecular Medicine, 2009, 87, 971-980.	1.7	17
84	The tryptophan 620 allele of the lymphoid tyrosine phosphatase (<i>PTPN22</i>) gene predisposes to autoimmune Addison's disease. Clinical Endocrinology, 2009, 70, 358-362.	1.2	42
85	Genetics of Type 1 Diabetes and Autoimmune Thyroid Disease. Endocrinology and Metabolism Clinics of North America, 2009, 38, 289-301.	1.2	24
86	Preface. Endocrinology and Metabolism Clinics of North America, 2009, 38, xvii-xviii.	1.2	0
87	An elderly woman with weight loss and diarrhoea. BMJ: British Medical Journal, 2009, 338, b1721-b1721.	2.4	Ο
88	Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clinical Endocrinology, 2008, 68, 814-820.	1.2	64
89	Management of hypothyroidism in adults. BMJ: British Medical Journal, 2008, 337, a801-a801.	2.4	122
90	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	1.9	611

#	Article	IF	CITATIONS
91	Unrecognised severe vitamin D deficiency. BMJ: British Medical Journal, 2008, 336, 1371-1374.	2.4	29
92	Mutations in <i>Prokineticin 2</i> and <i>Prokineticin receptor 2</i> genes in Human Gonadotrophin-Releasing Hormone Deficiency: Molecular Genetics and Clinical Spectrum. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3551-3559.	1.8	190
93	Polymorphisms in <i>CLEC16A</i> and <i>ClITA</i> at 16p13 Are Associated with Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3310-3317.	1.8	108
94	The Influence of Age on the Relationship between Subclinical Hypothyroidism and Ischemic Heart Disease: A Metaanalysis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2998-3007.	1.8	279
95	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	2.4	342
96	Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. Journal of Clinical Investigation, 2008, 118, 2822-2831.	3.9	348
97	Time to go to get your hat. BMJ: British Medical Journal, 2008, 337, a1130-a1130.	2.4	0
98	Left Ventricular Apical Ballooning (Takotsubo Cardiomyopathy) in Thyrotoxicosis. Thyroid, 2007, 17, 181-182.	2.4	24
99	Reversal of Idiopathic Hypogonadotropic Hypogonadism. New England Journal of Medicine, 2007, 357, 863-873.	13.9	362
100	Do antithyroid drugs influence outcome after radioiodine therapy for hyperthyroidism?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 628-629.	2.9	1
101	Analysis of the Fc Receptor-Like-3 (FCRL3) Locus in Caucasians with Autoimmune Disorders Suggests a Complex Pattern of Disease Association. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1106-1111.	1.8	83
102	Genomic Polymorphism at the Interferon-Induced Helicase (IFIH1) Locus Contributes to Graves' Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3338-3341.	1.8	104
103	Cytotoxic T-Lymphocyte–Associated Antigen-4 Single Nucleotide Polymorphisms and Haplotypes in Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2007, 5, 755-760.	2.4	35
104	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	9.4	1,298
105	FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nature Genetics, 2007, 39, 721-723.	9.4	421
106	Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. Journal of Clinical Investigation, 2007, 117, 457-463.	3.9	338
107	Genetic association studies of the FOXP3 gene in Graves' disease and autoimmune Addison's disease in the United Kingdom population. Journal of Molecular Endocrinology, 2006, 37, 97-104.	1.1	72
108	Genetic progress towards the molecular basis of autoimmunity. Trends in Molecular Medicine, 2006, 12, 90-98.	3.5	69

#	Article	IF	CITATIONS
109	What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. European Journal of Endocrinology, 2006, 154, 783-786.	1.9	44
110	No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves' disease. Clinical Endocrinology, 2005, 62, 362-365.	1.2	16
111	Role of the CD40 Locus in Graves' Disease. Thyroid, 2004, 14, 506-509.	2.4	55
112	The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. European Journal of Endocrinology, 2004, 150, 619-626.	1.9	107
113	Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clinical Endocrinology, 2004, 61, 589-594.	1.2	101
114	Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. European Journal of Pediatrics, 2004, 163, 589-594.	1.3	92
115	Toward Precise Forecasting of Autoimmune Endocrinopathy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 544-547.	1.8	29
116	Genetics in Endocrinology. Clinical Endocrinology, 2003, 59, 537-537.	1.2	1
117	Extracellular calcium-sensing receptor dysfunction is associated with two new phenotypes. Clinical Endocrinology, 2003, 59, 419-421.	1.2	13
118	The deleted in colorectal carcinoma (DCC) gene 201 R → G polymorphism: no evidence for genetic association with autoimmune disease. European Journal of Human Genetics, 2003, 11, 840-844.	1.4	2
119	Mutational Analysis of the FOXP3 Gene and Evidence for Genetic Heterogeneity in the Immunodysregulation, Polyendocrinopathy, Enteropathy Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 6034-6039.	1.8	104
120	Rapid onset childhood cataracts leading to the diagnosis of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. American Journal of Ophthalmology, 2003, 136, 951-952.	1.7	6
121	Disordered calcium crystal handling in antisense CLC-5-treated collecting duct cells. Biochemical and Biophysical Research Communications, 2003, 300, 305-310.	1.0	16
122	Clinical disorders of extracellular calcium-sensing and the molecular biology of the calcium-sensing receptor. Annals of Medicine, 2002, 34, 201-206.	1.5	32
123	The Genetics of Autoimmune Thyroid Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5385-5397.	1.8	154
124	Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary, 2002, 5, 243-246.	1.6	33
125	Clinical disorders of extracellular calcium-sensing and the molecular biology of the calcium-sensing receptor. Annals of Medicine, 2002, 34, 201-206.	1.5	1
126	Clinical disorders of extracellular calcium-sensing and the molecular biology of the calcium-sensing receptor. Annals of Medicine, 2002, 34, 201-6.	1.5	6

#	Article	IF	CITATIONS
127	Evidence for a Graves' Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 626-630.	1.8	54
128	Recent advances in the molecular genetics of congenital and acquired primary adrenocortical failure. Clinical Endocrinology, 2000, 53, 403-418.	1.2	37
129	CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. Journal of Hepatology, 2000, 32, 538-541.	1.8	169
130	Mapping of a novel tumour suppressor gene with a role in neuroendocrine tumours. Clinical Endocrinology, 1999, 51, 19-20.	1.2	0
131	Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clinical Endocrinology, 1999, 50, 691-693.	1.2	47
132	Extracellular "calcistat―in health and disease. Lancet, The, 1999, 353, 83-84.	6.3	30
133	Linkage Studies of a Missouri Kindred with Autosomal Dominant Spondyloepimetaphyseal Dysplasia (SEMD) Indicate Genetic Heterogeneity. Journal of Bone and Mineral Research, 1997, 12, 1204-1209.	3.1	10
134	Multiple endocrine neoplasia type 1 (MEN1): recent advances. Clinical Endocrinology, 1997, 47, 513-514.	1.2	3
135	A common molecular basis for three inherited kidney stone diseases. Nature, 1996, 379, 445-449.	13.7	694
136	Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH. Human Genetics, 1995, 96, 183-187.	1.8	61
137	Chronic hypernatremia due to impaired osmoregulated thirst and vasopressin secretion. European Journal of Endocrinology, 1991, 125, 234-239.	1.9	10